Synergistic anti-candidal activity of tetrandrine on ketoconazole: An experimental study

Planta Medica

Volumn 76, Issue 1, 2010, Pages 53-61

  Zhang, Hong ^a   Wang, Kaili ^a   Zhang, Gehua ^b   Ho, Hon In ^a   Gao, Aili ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antifungal susceptibility testing; Candida albicans; Ketoconazole; Synergism; Tetrandrine

Indexed keywords

FLUCONAZOLE; KETOCONAZOLE; TETRANDRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL COUNT; CANDIDA ALBICANS; CANDIDIASIS; CELL COUNT; CELL INFILTRATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; EDEMA; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; RANDOMIZATION; TECHNIQUE; VAGINA MUCOSA; VAGINAL LAVAGE; VAGINITIS;

ANIMALS; ANTIFUNGAL AGENTS; BENZYLISOQUINOLINES; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FEMALE; KETOCONAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUCOUS MEMBRANE; PHYTOTHERAPY; RANDOM ALLOCATION; STEPHANIA TETRANDRA; VAGINA; VAGINITIS;

CANDIDA ALBICANS; MUS;

EID: 74349093406     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185973     Document Type: Article

References (28)

1. Almirante B, Rodríguez D, Park B J., Cuenca-Estrella M, Planes A M., Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin S K., Morgan J, Rodriguez-Tudela J L., Warnock D W., Pahissa A. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005 43 1829-1835
2. Chattopadhyay A, Gray L R., Patton L L., Caplan D J., Slade G D., Tien H C., Shugars D C. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun 2004 72 1956-1963
3. Beck-Sagué C M., Jarvis W R. The National Nosocomial Infection Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 19801990. J Infect Dis 1993 167 1247-1251
4. Rex J H., Bennett J E., Sugar A M., Pappas P G., van der Horst C M., Edwards Jr J E., Washburn R G., Scheld W M., Karchmer A W., Dine A P., Levenstein M J., Douglas Webb C. The Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994 331 1325-1330
5. Edwards Jr J E., Bodey G P., Bowden R A., Büchner T, de Pauw B E., Filler S G., Ghannoum M A., Glauser M, Herbrecht R, Kauffman C A., Kohno S, Martino P, Meunier F, Mori T, Pfaller M A., Rex J H., Rogers T R., Rubin R H., Solomkin J, Viscoli C, Walsh T J., White M. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997 25 43-59
6. Hazen K C., Baron E J., Lopes Colombo A, Girmenia C, Sanchez-Sousa A, del Palacio A, de Bedout C, Gibbs D L. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003 41 5623-5632
7. Li F, Zhang H. In vitro study of the synergistic effect of tetrandrine and fluconazole against Candida albicans. Chin J Dermatol 2006 39 454-456
8. Wang K, Zhang H, Jiang H, Shi J, Gao A, Ho H, Chao H. In vitro study on tetrandrine as a synergist to fluconazole in murine model of vaginal candidiasis. Chin J Zoonoses 2007 23 474-478
9. White T C., Pfaller M A., Rinaldi M G., Smith J, Redding S W. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis 1997 3 S102-S109
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard [S]. NCCLS document M27-A. Wayne, Pennsylvania NCCLS 1997
11. Marchetti O, Moreillon P, Entenza J M., Vouillamoz J, Glauser M P., Bille J, Sanglard D. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 2003 47 1565-1570
12. Mukherjee P K., Sheehan D J., Hitchcock C A., Ghannoum M A. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005 18 163-194
13. Roling E E., Klepser M E., Wasson A, Lewis R E., Ernst E J., Pfaller M A. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002 43 13-17
14. Chen Z, Kong X. Study of Candida albicans vaginitis model in Kunming mice. J Huazhong Univ Sci Technolog Med Sci 2007 27 307-310
15. Fidel Jr P L., Cutright J L., Tait L, Sobel J D. A murine model of Candida glabrata vaginitis. J Infect Dis 1996 173 425-431
16. Lopez-Medrano R, Grupo de Microbiologos de la Sociedad Castellano-Leonesa de Microbilogia. Invasive aspergillosis in Castilla y Leon and Cantabria: years 1998 and 1999. Rev Iberoam Micol 2001 18 70-75
17. Wroblewsla M M., Swoboda-Kopec E, Rokosz A, Krawczyk E, Marchel H, Luczak M. Epidermiology of clinical isolates of Candida albicans and their susceptibility to triazoles. Int J Antimicrob Agents 2002 20 472-475
18. Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006 27 403-408
19. Canuto M M., Rodero F G. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002 2 550-563
20. Hossain M A., Reyes G H., Long L A., Mukherjee P K., Ghannoum M A. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003 51 1427-1429
21. Gil-Lamaignere C, Muller F M. C. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int J Antimicrob Agents 2004 23 520-523
22. Gao A, Zhang H, Mo H, Jiang H, Wang K, Chao H. Molecular mechanism of the synergy between tetrandrine and fluconazole against Candida albicans. Chin J Dermatol 2008 41 97-100
23. Zhang H, Gao A, Li F, Zhang G, Ho H, Liao W. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps. Yakugaku Zasshi 2009 129 623-630
24. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X, Pan Q. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 2004 53 349-356
25. Wang F P., Wang L, Yang J S., Nomura M, Miyamoto K I. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 2005 28 1979-1982
26. Wang G, Lemos J R. Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+)-activated K+ channels. Life Sci 1995 56 295-306
27. Liu L F., Chen N M., Cai G P., Li Z L., Yang J G., Li Y R. Studies on the effect of tetrandrine on microtubules. I. Biochemical observation and electron microscopy. Ecotoxicol Environ Saf 1988 15 142-148
28. Li F, Lu B, Chen W. Evaluation of the safety of tetrandrine loaded sustained release microcapsules for lung targeting. Chin J Mod Appl Pharm 2002 19 478-480